MESO$17.73
Chart
Performance
Key Stats
AI MESO Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldMesoblast shows mixed signals. While its core technology in regenerative medicine and potential in treating inflammatory diseases present a thematic opportunity, its financial performance is characterized by significant losses and negative cash flow. Technical indicators are bearish across multiple timeframes, suggesting potential further downside. Investors should approach with caution, focusing on the long-term potential of its drug pipeline rather than short-term price action.
Thematic
Mesoblast operates in the high-growth regenerative medicine sector, with a focus on unmet medical needs in inflammatory diseases. The company's proprietary technology platform and ongoing clinical trials represent a significant thematic opportunity, particularly if its lead candidates achieve regulatory approval and market success.
Fundamental
Mesoblast exhibits weak financial fundamentals. It consistently reports significant net losses, negative earnings per share, and negative free cash flow. While it maintains substantial assets, its liabilities and current cash position suggest a need for careful financial management and potentially future capital raises.
Technical
Technical indicators for Mesoblast are overwhelmingly bearish across all analyzed timeframes. The stock is trading below key moving averages, and momentum indicators suggest further downward pressure. Price action indicates a strong downtrend.
| Factor | Score |
|---|---|
| Regenerative Medicine Potential | 85 |
| Clinical Trial Progress | 75 |
| Partnerships and Collaborations | 65 |
| Biotech Regulatory Landscape | 50 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 5 |
| Growth | 20 |
| Balance Sheet Health | 60 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 10 |
| Momentum | 40 |
| Volume Confirmation | 30 |
| Support & Resistance | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Improving Cash Position
Cash equivalents have increased from $60.03M in Q2 2022 to $62.56M in Q2 2024, indicating a healthier liquidity buffer.
Positive 1-Year Return
The stock has shown a positive return of 48.51% over the last year, indicating a period of strong performance.
Bearish Points (8)
Recent Price Decline
The stock price has decreased by -1.88% recently, with a -1.88% performance over the last 5 days, indicating a short-term downward trend.
Consistent Net Losses and Margin Compression
The company has reported significant net losses in the last four quarters, with net margins ranging from -894.6% to -1490.3%, indicating severe profitability issues. Revenue has also declined from $10.21M in Q2 2022 to $5.90M in Q2 2024.
Calendar
August 2025
29
Next Earnings Date
H: $
A: $
L: $
H: 7.48M
A: 7.48M
L: 7.48M
Profile
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Seasonals
Price Target
27.00 USD
The 39 analysts offering 1 year price forecasts for MESO have a max estimate of 30.00 and a min estimate of 24.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Acquired TiGenix, a direct competitor of Mesoblast in allogeneic stem cell therapies (e.g., Darvadstrocel for Crohn's fistula), representing direct market relevance and competition in specific disease areas.
Weight: 90
Developing MultiStem, an allogeneic mesenchymal stem cell product, for similar indications such as stroke and ARDS, representing a direct technological and pipeline overlap with Mesoblast's allogeneic MSC platform.
Weight: 88
Focused on allogeneic cell therapy (CAP-1002) for cardiac conditions and Duchenne Muscular Dystrophy, sharing Mesoblast's foundational allogeneic cell therapy platform and targeting similar therapeutic areas (heart failure).
Weight: 85
Develops allogeneic placental-derived cell therapies for conditions like acute radiation syndrome and muscle regeneration, employing a similar 'off-the-shelf' allogeneic approach in regenerative medicine.